Teva Launches First Generic to Blockbuster Cancer Med

This is the first generic available for Revlimid in the United States.

Teva Pharmaceuticals launched lenalidomide, the first generic version of Celgene Corp.’s blockbuster cancer treatment Revlimid (lenalidomide capsules).

Revlimid, which treats multiple myeloma in combination with dexamethasone (Decadron, other brand names), myelodysplastic syndromes (specifically patients with a deletion of some part of chromosome 5), and mantle cell lymphoma, had annual sales of $2.3 billion as of 2021, according to IQVIA, Teva said in a news release.

Lenalidomide capsules will be available immediately in the United States in 5 mg, 10 mg, 15, mg, and 25 mg strengths. The drug also treats certain myelodysplastic syndromes.

“The launch of our first generic version of Revlimid in the United States provides patients with another important treatment option for these extremely challenging conditions, demonstrating Teva’s commitment to making complex generic drugs available to the patients who need them,” said Christine Baeder, senior vice president and chief operating officer of U.S. generics at Teva USA.

Lenalidomide adds to Teva’s generic portfolio of oncology treatments, which accounts for 73% of the essential medicines in this category, according to the company.

Additionally, Sandoz recently announced that it has launched a generic of lenalidomide in 19 countries across Europe.